← FDA DRUG APPROVALS

FDA ANDA · ANDA203311

VALSARTAN

Sponsor: HETERO LABS LTD V

APPLICATION
ANDA203311
TYPE
ANDA
ORIGINAL APPROVAL
2015-01-05
LATEST ACTION
2021-12-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

VALSARTANPrescription
VALSARTAN 160MG · TABLET · ORAL
VALSARTANPrescription
VALSARTAN 40MG · TABLET · ORAL
VALSARTANPrescription
VALSARTAN 320MG · TABLET · ORAL
VALSARTANPrescription
VALSARTAN 80MG · TABLET · ORAL

Approval history

2021-12-07Labeling · Supplement 15 · standardAP
2021-12-07Labeling · Supplement 16 · standardAP
2019-11-06Labeling · Supplement 5 · standardAP
2019-11-06Labeling · Supplement 3 · standardAP
2019-11-06Labeling · Supplement 9 · standardAP
2015-01-05UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →